Rein Therapeutics (015A) Stock Price & Analysis
015A Stock Chart & Stats
- Day’s Range
- EUR 3.14 - EUR 3.30
- 52-Week Range
- EUR 3.14 - EUR 3.30
- Previous Close
- EUR 3.14
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 51.75M
- Enterprise Value
- EUR 74.13M
- Total Cash (Recent Filing)
- EUR 40.65M
- Total Debt (Recent Filing)
- EUR 0
- Price to Earnings (P/E)
- ―
- Beta
- N/A
- Next Earnings
- Nov 06, 2026 (Est.)
- EPS Estimate
- -0.09
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Clinical Validation And Phase 2 Progress
LTI-03 has advanced beyond early safety testing with a met Phase 1b primary endpoint and tolerability at both tested doses. Enrollment in Phase 2 gives the lead program a clearer development path and creates an opportunity to validate efficacy in IPF.
Potentially Differentiated Antifibrotic Mechanism
The company is pursuing a mechanism intended to restore alveolar structure and affect multiple profibrotic pathways, rather than simply duplicating existing approaches. If clinical results support this thesis, the platform could provide differentiation in IPF and related pulmonary fibrosis indications.
Debt-free Balance Sheet
Zero reported debt limits interest burden and financial leverage, giving Rein greater flexibility than a similarly loss-making company carrying substantial borrowings. The rebound in equity also indicates improved capitalization, although continued losses could weaken this cushion over time.
Bears Say
Pre-revenue Business With Substantial Losses
Rein has no commercial revenue to offset research and operating costs, while its nearly $49.8M TTM net loss shows that the business remains far from self-sustaining. Future financial strength therefore depends heavily on successful development and eventual commercialization.
Persistent Cash Consumption And Funding Dependence
Continued negative operating and free cash flow means Rein is consuming capital rather than funding operations internally. Even with some improvement from 2024, sustained burn increases dependence on external financing or strategic transactions before product revenue can emerge.
Nasdaq Listing Compliance Risk
The delisting notice creates an ongoing corporate and financing risk because failure to restore the required bid price could lead to suspension and delisting. That outcome could reduce market access and complicate the capital raising needed to fund clinical development.
015A FAQ
What was Rein Therapeutics’s price range in the past 12 months?
What is Rein Therapeutics’s market cap?
When is Rein Therapeutics’s upcoming earnings report date?
How were Rein Therapeutics’s earnings last quarter?
Is Rein Therapeutics overvalued?
Does Rein Therapeutics pay dividends?
What is Rein Therapeutics’s EPS estimate?
How many shares outstanding does Rein Therapeutics have?
What happened to Rein Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Rein Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Rein Therapeutics Stock Smart Score
Company Description
Rein Therapeutics
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- James Brian Windsor
- Employees
- 10
- Website
- www.reintx.com
- Address
- 12407 N. Mopac Expy., Austin, TX, 78758, US
Rein Therapeutics (015A) Earnings & Revenues
015A Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 4 | 4 |
| Technical Analysis | 2 | 0 | 0 |
| Moving Averages | 4 | 4 | 4 |
